The Latest Breaking News from Merck

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts.

These companies have faced setbacks, but I'm confident their stock prices will flourish once again.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

Indexes were mixed early Wednesday. Nvidia added gains after clearing a trendline entry on Tuesday. Trump Media & Technology soared.

Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.